Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697744 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL239122 | 0.79 | CYP2A6 (0.37) | CYP2A6CYP1A2HPGDALDH1A1TDP1 | |
| SCHEMBL3249728 | 0.77 | ALDH1A1 (0.34) | CYP2A6CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL668159 | 0.77 | ALDH1A1 (0.41) | CYP2A6CYP1A2SMN1; SMN2TP53HPGD | |
| SCHEMBL667984 | 0.77 | ALDH1A1 (0.34) | CYP2A6RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL4609078 | 0.77 | MAPK1 (0.39) | CYP2A6RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL10501303 | 0.77 | ALDH1A1 (0.39) | CYP1A2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3246275 | 0.77 | NPC1 (0.37) | CYP1A2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20774242 | 0.74 | HPRT1 (0.50) | CYP2A6CYP1A2TP53HPGDALDH1A1 | |
| SCHEMBL668632 | 0.74 | ALDH1A1 (0.38) | CYP2A6CYP1A2SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101977883-A | Process for production of 2-hydroxyaryl aldehyde compound | NISSAN CHEMICAL IND LTD | 2011-02-16 | — | — | CN | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6066672-A | OF GIVEN FORMULA COMPRISING A SUBSTITUTED AMINOALKYL(AMIDO OR ALKYLAMINO)ALKYL(AMIDO OR ALKYLAMINO)ALKYL(ALKENE, ALKYL OR ALKOXYCARBONYL) | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0882699-A1 | AMINO COMPOUNDS AND ANGIOTENSIN IV RECEPTOR AGONISTS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5124342-A | Antiinflammatory, antiarthritic agents; antiallergens; skin disorders | ABBOTT LABORATORIES (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0457803-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4992464-A | Bronchodilator, antiinflammatory, antiarthritic, antiallergenic agents | ABBOTT LABORATORIES (US) | 1991-02-12 | — | — | US | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990009381-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-08-23 | — | — | WO | disclosed |
| US-4895587-A | Haloacetamide compounds, process for production thereof, and use thereof as herbicide | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0229290-A2 | Stabilized thermoplastic moulding compositions based on ABS polymers and acryl phosphanoxides | BAYER AG (DE) | 1987-07-22 | — | — | EP | disclosed |
| EP-0206251-A1 | Haloacetamide compounds, process for production thereof, and use thereof as herbicide | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | CYP2A6 2385/4885CYP1A2 1561/4885NPC1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.